The metabolic syndrome: Overeating, inactivity, poor compliance or 'dud' advice?

Diabetic Medicine

Volumn 15, Issue SUPPL. 3, 1998, Pages

  Petrie, J R ^a   Cleland, S J ^a   Small, M ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SYNDROME X;

ADULT; CARDIOVASCULAR DISEASES; EXERCISE; GLUCOSE INTOLERANCE; HUMANS; HYPERPHAGIA; OBESITY; PATIENT COMPLIANCE; SYNDROME;

EID: 0031766922     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9136(1998110)15:3+3.3.co;2-o     Document Type: Review

References (25)

1. Braunwald E. Cardiovascular medicine at the turn of the millenium: triumphs, concerns, and opportunities. New Engl J Med 1997; 337: 1360-1369.
2. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome. Diabetes 1992; 41: 715-722.
3. Camus JP. Goutte, diabéte, hyperlipémie: un trisyndrome métabolique. Rev Rheumat 1966; 33: 10-14.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1495-1507.
5. O'Rahilly S. Non-insulin-dependent diabetes mellitus: the gathering storm. BMJ 1997; 314: 955-959.
6. Foreyt J, Goodrick K. The ultimate triumph of obesity. Lancet 1995; 346: 134-135.
7. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306: 1313-1318.
8. NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann Intern Med 1993; 119: 764-770.
9. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991; 303: 953-957.
10. Eriksson J, Taimela S, Koivisto VA. Exercise and the metabolic syndrome. Diabetologia 1997; 40: 125-135.
11. Lichtman SW, Pisarka K, Berman ER, Pestone M, Dowling H, Offenbacher E, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. New Engl J Med 1992; 327: 1893-1898.
12. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
13. Gotto AM. AFCAPS/TexCAPS. Presented at the 70th Scientific Sessions of the American Heart Association, Orlando, Florida, March 1997.
14. Sacks FM, Pfeffer MA, Moye LA, Rolleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-1009.
15. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KH, Godwin I, Qizilbach N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
16. Guy-Grand B, Apfelbaum M, Crepaldi G, Gris A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: 1142-1145.
17. Petrie JR, Connell JMC, Small M. Clitazones: new prospects for therapy in NIDDM. Lancet 1997; 349: 70-71.
18. Waldhausl W. Where do we want to go? Diabetologia 1998; 41: 1.
19. Zimmet P, Lefèbvre P. The global NIDDM epidemic: treating the disease and ignoring the symptom. Diabetologia 1996; 39: 1247-1248.
20. Zimmet PZ. Challenges in diabetes epidemiology: from West to the Rest. Diabetes Care 1992; 15: 232-252.
21. O'Dea K. Westernisation, insulin resistance and diabetes in Australian aborigines. Med J Aust 1991; 155: 258-264.
22. Neel JV. Diabetes mellitus: a 'thrifty' genotype rendered detrimental by 'progress'? Am J Human Genetics 1962; 14: 353-362.
23. Swinburn BA. The thrifty genotype hypothesis: how does it look after 30 years? Diabetic Med 1996; 13: 695-699.
24. Chagnon YC, Bouchard C. Genetics of obesity: advances from rodent studies. Trends Genet 1996; 12: 441-444.
25. Hales CN, Desai M, Ozanne SE. The thrifty phenotype hypothesis: how does it look after 5 years? Diabetic Med 1997; 14: 189-195.